WT1 protein expression was associated with shorter overall survival in melanoma (Garrido-Ruiz et al., 2010) and deemed as a target antigen for immunotherapy since a novel signaling mechanism mediated by PPARbeta ligands, which led to melanoma cell growth suppression through the direct repression of WT1, was described (Michiels et al., 2010, 1). Here, WT1 is linked to melanoma.